Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…Clinico-genetic analysis of patients with Parkinson’s disease and GBA mutations from a tertiary care teaching centre in India
Objective: To describe the clinico-genetic association of PD patients with heterozygous GBA mutations (PDwG). Background: Parkinson’s disease (PD) is currently understood to be the outcome…Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease
Objective: The aim was to explore the correlations between Jumping to Conclusions (JtC) tendency and neuropsychiatric features in patients with early Parkinson’s disease (PD). Background:…Clozapine Therapy for Parkinson’s Disease Psychosis: A 21-Year Service Analysis
Objective: To review the demographic aspects, safety, and efficacy of Clozapine treatment for Parkinson’s Disease Psychosis (PDP) in a large patient cohort. Background: The impact…Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.
Objective: Perform a systematic review of the literature about the efficacy of quetiapine in the treatment of psychosis in patients with Lewy’s Body Dementia. Background:…Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review
Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials
Objective: This systematic review and meta-analysis aimed to assess the safety profile of pimavanserin in Parkinson’s disease psychosis (PDP) patients from the available randomized controlled…Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.
Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »